Clinical trial · Interventional
Effect of Transcutaneous Electrical Nerve Stimulation on CIPN Symptoms
Effects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-induced Peripheral Neuropathy Symptoms
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and debilitating survivorship conditions for patients with cancer, and one of the most common side effects of chemotherapy treatment. Unfortunately, there are no proven ways to prevent or treat CIPN. Transcutaneous electrical nerve stimulation (TENS) is a method that succeeded to treat different types of pain and needs more investigation on its effect on CIPN. Aim : The aims of this study are to investigate the effect of TENS in reducing CIPN symptoms in patients with cancer and to investigate the relathionship between some of the patients' sociodemographic charestristics/ medical history and the levels of CIPN after treatment with TENS. Method : A double blind parallel randomized controlled trial (RCT) will be used in this study to assess the effect of TENS on CIPN among patients with cancer treated with chemotherapy. Participants will be recruited from King Hussein Cancer Center (KHCC). 44 patients will be included in the study if they developed CIPN after the first cycle of chemotherapy treatment, were ≥18 years old, and were not previously received any session of TENS device and only on gabapentin drug currently. Patients will be randomly assigned to one of two groups, 22 patient for each group. The intervention group will receive the TENS sessions daily for 10 days and for 30 minutes each session. The control group will stay on gabapentin. CIPN will be assessed using the Arabic Version of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool. CIPN will be assessed three time during the study: first time will be pre-intervention, second time will be after 5 days of treatment and the third time will be at the end of the sessions. Implication : The result will lead nursing to achieve optimal nursing care for all patients by controlling the pain level and improve other peripheral neuropathy symptoms .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy-induced Peripheral Neuropathy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Transcutaneous electrical nerve stimulation | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Interventional group
- description
- The interventional group (n=22) will receive TENS sessions in addition to the prescribes medication (Gabapentinoids). The assessment will be performed at three time points also; before the begging of the intervention, after 5 days, and after the last session.
- interventionNames
- Device: Transcutaneous electrical nerve stimulation
- type
- NO_INTERVENTION
- label
- Control group
- description
- The control group The control group (n=22) will stay on the prescribed oral medication (Gabapentinoids) for at least 4 weeks (Hirayama et al.,2015). The assessment will be performed at three time points by the primary investigator using the Arabic version of CIPNAT . The first assessment will take place prior to the start of the trial, after two weeks of taking the medication, and the final assessment will be done after 4 weeks of receiving oral agents.
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients will be invited if they ≥18 years * were not previously received any session of TENS device * on gabapentin drug currently Exclusion Criteria: * skin conditions (lesions or open sores) * cognitive difficulties or trouble understanding * history of peripheral neuropathy due to receiving neurotoxic chemotherapy * cardiac pacemakers * have ever used TENS device treatment * chronic conditions (diabetes mellitus, brain damage, history of epilepsy, or taking anticonvulsants drugs) * pregnant women
References
Publications (0)
Data not yet available